Table 1.

Clinical trial results

PATIENT	AREA TREATED	BEFORE	2 TX	3 TX	4 TX	5 TX	6 TX	1-MONTH FOLLOW UP	3-MONTH FOLLOW UP	ADVERSE EVENTS	2 TX %	3 TX %	4 TX %	5 TX %	6 TX %	1-MONTH FOLLOW UP %	3-MONTH FOLLOW UP %
EDZ	R AX	49	31	37	9	7	3	4	6	None	63%	76%	18%	14%	6%	8%	12%
KSS	L +RAX	62	65	36	24	18	4	3	10	None	105%	58%	39%	29%	6%	5%	16%
LB	R+L AX	27	18	15	13	9	4	2	3	None	67%	56%	48%	33%	15%	7%	11%
PH	R+L AX	30	11	2	3			2	0	None	37%	7%	10%	0%	0%	7%	0%
JLH	R+L AX	36	24	29	19	22	14	3	7	None	67%	81%	53%	61%	39%	8%	19%
CMC	R+L AX	14	15	12	7	4	11	8	5	None	107%	86%	50%	29%	79%	57%	36%
KML	R+L AX	33	26	5	19	13	7	3	3	None	79%	15%	58%	39%	21%	9%	9%
EAR	BL	57	17	12	18	32	20	16	20	None	30%	21%	32%	56%	35%	28%	35%
LAB R+L	AX	48	36	20	29	21	14	12	6	None	75%	42%	60%	44%	29%	25%	13%
I-N R+L	AX	53	33	14	23	10	10	7	4	None	62%	26%	43%	19%	19%	13%	8%
AGB R+L	AX	58	67	39	37	35	43	28	30	None	116%	67%	64%	60%	74%	48%	52%
AMM R+L	AX	26	10	6	9	8		15	12	None	38%	23%	35%	31%	0%	58%	46%
LHW R	AX	18	21	10	10	10		5	14	None	117%	56%	56%	56%	0%	28%	78%
D-N R+L	AX	23	19	10	4	15	7	5	11	None	83%	43%	17%	65%	30%	22%	48%
MRG R	AX	19	13	8	5	19		2	3	None	68%	42%	26%	100%	0%	11%	16%
L-P R	AX	38	17	12	5	6		4	7	None	45%	32%	13%	16%	0%	11%	18%
CGS R	AX	23	13	7	7	3	3	5	5	None	57%	30%	30%	13%	13%	22%	22%
AGG R	AX	44	39	23	10	15	10	10	12	None	89%	52%	23%	34%	23%	23%	27%
JTR R	AX	29	25	8	8	14	2	3	10	None	86%	28%	28%	48%	7%	10%	34%
JFS R	AX	22	10	10	8		6	8	14	None	45%	45%	36%	0%	27%	36%	64%
Average Clearance																22%	28%